Business
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
SAN ANTONIO, February 25, 2026--bioAffinity Technologies announced validation study with BAMC to assess deep suction sputum samples for lung cancer detection with CyPath Lung.
About this update from Bioaffinity Technologies, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":201,"url":"https://media.zenfs.com/en/business-wire.com/03a4d8c760d242bc6df596989d98ce74"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.J1_bSKZ.auwBY6b7xjGjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/03a4d8c760d242bc6df596989d98ce74","width":480,"height":201}},"lazy":false},{"type":"text","content":"Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung","length":108,"tagName":"p","attribs":{}},{"type":"text","content":"SAN ANTONIO, February 25, 2026--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a new study with Brooke Army Medical Center (BAMC) to validate the clinical utility of using the CyPath® Lung diagnostic test to assess sputum samples obtained by tracheal and bronchial suctioning for early detection of lung cancer.","length":438,"tagName":"p"},{"type":"text","content":"The study is designed to enroll approximately 30-50 patients undergoing routine tracheal or bronchial suctioning, with results from the study expected by mid-year 2026. Validating the performance of CyPath® Lung analysis on deep suction samples has the potential to expand the versatility of CyPath® Lung and support broader use in the detection of early-stage lung cancer.","length":373,"tagName":"p"},{"type":"text","content":""CyPath® Lung is a novel, noninvasive adjuvant diagnostic for patients at high risk for lung cancer," said Michael J. Morris, MD, pulmonology and critical care physician at BAMC. "The ability to use CyPath® Lung to analyze suctioned sputum collected during bronchoscopy and other procedures would leverage samples that we are already obtaining and expand access to earlier, more informed decision-making for patients at risk."","length":446,"tagName":"p"},{"type":"text","content":""Clinicians who have patients scheduled to undergo diagnostic bronchoscopy have told us that CyPath® Lung could be very helpful by providing an independent and complementary test for diagnosis," said Gordon Downie, MD, PhD, Chief Medical Officer of bio...